Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/11000/30859
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.authorCampo, Paloma-
dc.contributor.authorPlaza-Serón, María del Carmen-
dc.contributor.authorEguiluz-Gracia, Ibon-
dc.contributor.authorVerge, Jesús-
dc.contributor.authorGalindo, Luisa-
dc.contributor.authorBarrionuevo, Esther-
dc.contributor.authorFernández, Javier-
dc.contributor.authorJurado, Raquel-
dc.contributor.authorMAYORGA, CRISTOBALINA-
dc.contributor.authorTorres, Maria José-
dc.contributor.authorRondón, Carmen-
dc.contributor.otherDepartamentos de la UMH::Medicina Clínicaes_ES
dc.date.accessioned2024-01-31T10:48:11Z-
dc.date.available2024-01-31T10:48:11Z-
dc.date.created2018-
dc.identifier.citationInternational Forum of Allergy & Rhinology, Vol. 8, No. 1, January 2018es_ES
dc.identifier.issn2042-6984-
dc.identifier.issn2042-6976-
dc.identifier.urihttps://hdl.handle.net/11000/30859-
dc.description.abstractThe measurement of nasal specific IgE (NsIgE) in local allergic rhinitis (LAR) patients is challenging and shows variability. The objective of this work was to evaluate a minimally-invasive method of direct detection of NsIgE in patients with LAR to Dermatophagoides pteronyssinus (DP) using an automated immunoassay. Methods: Fifty patients participated (LAR, n = 14; allergic rhinitis (AR), n = 20; healthy controls [HC], n = 16). Detection of NsIgE was performed by direct application of the solid phase of a commercialDPImmunoCAP ® test 24 hours a er DP nasal provocation. Results: There was no difference in the median volume of secretion absorbed by the solid phase of the Immuno- CAP test in the 3 studied groups (p = 0.17). According to receiver operating characteristic (ROC) curve analysis. NsIgE 0.1450 was the optimal cutoff point, obtaining in LAR patients 42.86% sensitivity with the highest specificity (100%), and 75% sensitivity and 100% specificity for AR. Conclusion: This study demonstrates the detection of NsIgE to DP in LAR by using a simple, commercial device with high specificity.es_ES
dc.formatapplication/pdfes_ES
dc.format.extent5es_ES
dc.language.isoenges_ES
dc.publisherWileyes_ES
dc.rightsinfo:eu-repo/semantics/closedAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectlocales_ES
dc.subjectnasales_ES
dc.subjectrhinitises_ES
dc.subjectsensitivityes_ES
dc.titleDirect intranasal application of the solid phase of ImmunoCAP ® increases nasal specific immunoglobulin E detection in local allergic rhinitis patientses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttps://doi.org/10.1002/alr.22039es_ES
Aparece en las colecciones:
Artículos Medicina Clínica


no-thumbnailVer/Abrir:

 Direct intranasal application of the solid phase of ImmunoCAP.pdf



881,15 kB
Adobe PDF
Compartir:


Creative Commons La licencia se describe como: Atribución-NonComercial-NoDerivada 4.0 Internacional.